Background and Aims

The purpose is to examine the adiponectin polymorphism ADIPQQ-g93054571A > G and its association with adiponectin concentration in the serum, to research the effect of sugar-lowering therapy on adiponectin levels.

Methods

58 patients with type 2 DM were examined, 28 used metformin, 30 used insulin.

The average age at the time of the survey was 56.65 ± 1.51 years. Disease duration averaged 5.8 ± 3.5 years.

The serum concentration of adiponectin was determined by ELISA (Germany) using the Mediagnost E09 Adiponectin test kit. Insulin resistance was calculated with HOMA-IR index; glycated hemoglobin (HbA1).

The polymorphism of adiponektin (ADIPQQ-g93054571 A > G) was conducted by the method of using MALDI-TOF mass spectrometer company Sequenom (USA).

Results

The average value of glycosylated hemoglobin amounted to

8.66 ± 2.2%. Adiponectin median was 11.78 ± 4.32 mg / ml in patients taking metformin, and -3.52 ± 2.02 mg / ml in patients taking insulin. HOMA-IR on metformin was 5.15-3.32 μg / ml, on insulin it was 17.23 ± 9.78 μg / ml

According to our data, the ratio of Adiponectin / Homa (A / H) on the background of therapy with Metformin was 2.29 , while with insulin it was 0.204.

Conclusions

The results confirm the need to include metformin in the treatment complex of patients with type 2 DM to increase adiponectin level. In patients taking metformin adiponectin content is significantly increased compared with the figure for insulin therapy, this is 3.35 times (p <0.01).

Metformin eliminates the phenomenon of “hyperglycemic memory”, normilizes weight and lipid metabolism.